Introduction to ArtificiaI Intelligence in Higher Education
ICH and Overview of ICH Guidelines..pptx
1. ICH & ICH Guidelines
By: Syed Arshiya
M. Pharmacy
(Pharmaceutical
Regulatory Affairs)
2. Introduction:
• ICH stands for “International Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use”.
• It is an initiative that brings together Regulatory authorities and Pharmaceutical
industry to discuss scientific and technical aspects of pharmaceutical product
development and registration.
3. History:
• In the 1980s the European Union began harmonising regulatory requirements.
• In 1989 Europe, Japan & United States began creating plans for harmonisation.
• ICH was founded in April 1990 at a meeting in Brussels.
4. Mission:
• To achieve greater harmonisation world wide.
• To protect the public health.
• To ensure that safe, effective, and high quality medicines are developed and
registered in the most efficient manner.
• To monitor and update harmonised technical requirements leading to a greater
acceptance of research and development data.
5. • To maintain a forum for on scientific issues between regulatory authorities and the
pharmaceutical industry on the harmonisation of the technical requirements for
pharmaceutical products.
11. ICH Guidelines:
The ICH topics are divided into the four categories below and ICH topic codes are
assigned according to these categories:
Q – Quality guidelines
S – Safety guidelines
E – Efficacy guidelines
M – Multidisciplinary guidelines
12. Quality Guidelines:
Guideline
Code
Title
Q1A – Q1F Stability
Q2 Analytical validation
Q3A – Q3E Impurities
Q4A – Q4B Pharmacopoeias
Q5A – Q5E Quality of biotechnological products
Q6A – Q6B specifications
Q7 Good manufacturing practice
13. Q8 Pharmaceutical development
Q9 Quality risk management
Q10 pharmaceutical quality system
Q11 Development and manufacture of drug substances
Q12 Life cycle management
Q13 Continuous manufacturing of drug substances and drug products
Q14 Analytical Procedure Development
16. Efficacy Guidelines:
Guideline
code
Title
E1 Clinical safety for drugs used in long term treatment
E2A – E2F Pharmacovigilance
E3 Clinical study reports
E4 Dose-response studies
E5 Ethic factors
E6 Good clinical practice
E7 Clinical trails in geriatric population
17. E8 General considerations for clinical trails
E9 Statistical principles for clinical trails
E10 Choice of control group in clinical trails
E11 – E11A Clinical trails in paediatric population
E12 Clinical evaluation by therapeutic category
E14 Clinical evaluation
E15 Definitions in pharmacogenetics/ pharmacogenomics
E16 Qualification of genomic biomarkers
18. E17 Multi regional clinical trails
E18 Genomic sampling
E19 Safety data collection
E20 Adaptive clinical trails
E21
Inclusion of pregnant and breastfeeding individuals in clinical
trails
19. Multidisciplinary Guidelines:
Guideline code Title
M1
MedDRA terminology
M2
Electronic standards
M3 Non clinical safety studies
M4
Common technical document
M5
Data elements and standards for drug dictionaries
M6
Gene therapy
M7
Mutagenic impurities
20. M8 Electronic common technical document (eCTD)
M9 Biopharmaceutics classification system based biowavers
M10 Bioanalytical method validation and study sample analysis
M11 Clinical electronic structured harmonised protocol (CeSHarP)
M12 Drug interaction
M13 Bioequivalence for immediate release solid oral dosage forms
M14 Use of real world data for safety assessment of medicines
M15 General principles for model informed drug development